Gastric cancer and esophageal cancer is a type of orphan cancer that occurs in the gastrointestinal tract. Due to a late onset of symptoms, these two cancers are often diagnosed at an advanced, almost incurable stage. However, they are still related to lesser survival rates in the early stages of disease.
According to research analysts, the global gastric cancer therapeutics market is growing. This increase is witnessed due to the rise in growth factor in terms of patients receiving gastric cancer therapy. It is also because the annual cost of therapy and medicines has increased in the pharmaceutical industry. All these value-driven factors are incessantly anticipating the market size, growth, and forecast period of this industry.
As per the statistics, the patient volume is mainly driven by an increase in the number of patients in countries such as Spain, Italy, France, and especially China. The incidences of gastric cancer in China are witnessed to be one of the highest across the globe, surpassing Japan and Korea, where the incident cases have increased 1.6 percent annually in China between 2010 and 2015. China and Japan lead the market due to a vast patient base in gastric cancer.
Gastric cancer has no standard care and the treatment of this cancer is typically based on different treatment guidelines followed in various countries. There are very few drugs that are truly approved for gastric cancer and currently the primary treatment options in this field are surgery and chemotherapy, which are used wherever possible.
ResearchMoz gastric cancer reports provide every elemental detail and information relating to the gastric cancer and clinical trials, trial status, briefing pertaining to the numbers of trials for key drugs, and more. Our reports are worth the purchase because every report elaborates the dynamics of a particular indication in a comprehensive and condensed manner. Browse through the updated collection of gastric cancer reports on ResearchMoz that consists of all the analysis and valuable insights into the global gastric cancer therapeutics market.